Dyne Therapeutics is a clinical-stage biotechnology company developing oligonucleotide therapies for serious muscle diseases. Its FORCE platform aims to deliver genetic medicines more effectively into muscle tissue, with programs targeting conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy. The company is pre-commercial and focused on advancing these candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -115.4 | — |
| Q2 2025 | 0 | — | -110.9 | — |
| Q3 2025 | 0 | — | -108 | — |
| Q4 2025 | 0 | — | -112 | — |
| Q1 2026 | 0 | — | -120.8 | — |
| Q2 2026 | 0 | — | -178.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Liberty Global Ltd. (LBTYA), Digi International Inc. (DGII), Astronics Corporation (ATRO), NBT Bancorp Inc. (NBTB), Central Garden & Pet Company (CENT), Liberty Global Ltd. (LBTYK)